Global Rosuvastatin Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Rosuvastatin Drugs Market Research Report 2024
Rosuvastatin is used along with a proper diet to help lower "bad" cholesterol and fats (such as LDL, triglycerides) and raise "good" cholesterol (HDL) in the blood. It belongs to a group of drugs known as "statins." It works by reducing the amount of cholesterol made by the liver. Lowering "bad" cholesterol and triglycerides and raising "good" cholesterol decreases the risk of heart disease and helps to prevent strokes and heart attacks.
According to Mr Accuracy reports’s new survey, global Rosuvastatin Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Rosuvastatin Drugs market research.
Key manufacturers engaged in the Rosuvastatin Drugs industry include AstraZeneca, Watson, ANGITA and Sun Pharmaceutical Industries, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % volume of Rosuvastatin Drugs were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Rosuvastatin Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rosuvastatin Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
AstraZeneca
Watson
ANGITA
Sun Pharmaceutical Industries
Segment by Type
5 mg Tablet
10 mg Tablet
20 mg Tablet
40 mg Tablet
Hyperlipidemia And Mixed Dyslipidemia
Familial Hypercholesterolemia
Hypertriglyceridemia
Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia)
Atherosclerosis
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Rosuvastatin Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Rosuvastatin Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Rosuvastatin Drugs market research.
Key manufacturers engaged in the Rosuvastatin Drugs industry include AstraZeneca, Watson, ANGITA and Sun Pharmaceutical Industries, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % volume of Rosuvastatin Drugs were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Rosuvastatin Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rosuvastatin Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
AstraZeneca
Watson
ANGITA
Sun Pharmaceutical Industries
Segment by Type
5 mg Tablet
10 mg Tablet
20 mg Tablet
40 mg Tablet
Segment by Application
Hyperlipidemia And Mixed Dyslipidemia
Familial Hypercholesterolemia
Hypertriglyceridemia
Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia)
Atherosclerosis
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Rosuvastatin Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source